This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provided information on the clinical laboratory tests that were conducted. Further interpretation and discussion of the data are demonstrated in the article "Revefenacin, a Once-daily, Lung-selective, Longacting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease." [1] 
Data
A schematic overview, which included the screening, treatment period, and follow-up visits, is shown in the Fig. In Table 1 , a detailed list of the medications that required washout or modification before screening and were prohibited. The full inclusion and exclusion criteria are shown in Table 2 . Table 3 provides a detailed overview of how adverse events (AEs), serious AEs (SAEs), and vital signs were evaluated. Tables 4e7 include data on drug exposure (revefenacin or tiotropium), clinical laboratory measurements, and vital signs.
Experimental design, materials, and methods

Schematic overview
Overall, there were one or two screening visits (Visit 1A/Visit 1B; depending on whether a washout period was required) and 6 treatment period visits (Visits , and a telephone follow-up visit (Visit 8, 7 ± 2 days after Visit 7 or early termination). Informed consent was obtained during the first screening visit (Visit 1A), and the subject's existing COPD medication was assessed to determine whether any adjustments were required to comply with the protocol.
If a washout period or a stable long-acting beta agonist (LABA)/inhaled corticosteroid (ICS) run-in period (at least 30 days) was required, the time from the Initial Screening Visit to Visit 1B was to be no longer than 45 days. If a washout period or a stable LABA/ICS run-in period (at least 30 days) was not required, then the two screening visits (Visit 1A and 1B) were conducted as a single screening visit (Visit 1A/B). The period from Visit 1B (i.e., the Ipratropium Reversibility Visit) to Day 1 of dosing (Visit Specifications Table   Subject area  Pulmonary and Respiratory Medicine  More specific subject  area   Chronic obstructive pulmonary disease   Type of data  Tables and Figure  How data 
Value of the data
The clinical laboratory tests and vital signs are important to determine the overall safety profile of treatments in patients with COPD. The experimental design and methods give further information on how the safety and tolerability data concerning patients with COPD were obtained. The safety profile of revefenacin was demonstrated in a broad population of patients with COPD of varying disease severity.
2) was 7e12 days (whether this was combined with Visit 1A or not). Eligible subjects were randomized on Visit 2 (Day 1 of dosing). 12. SABA 13. SAMA 6 hours before the ipratropium reversibility test at screening. Subjects will be provided with albuterol to be used as rescue medication during screening and throughout the treatment period. Albuterol must be withheld at least 6 hours before any spirometry performed. SAMA must be washed out before the ipratropium reversibility test and are prohibited throughout the treatment period.
Medications that required washout or modification before Visit 1B and were prohibited
Antibiotics
Any prophylactic use of antibiotics. ICS; inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting betaagonist; SAMA, short-acting muscarinic antagonist.
Table 2
Inclusion and exclusion criteria.
Inclusion criteria
1. Male and female subjects aged !40 years (age at Visit 1A).
2. Signed and dated written informed consent (Visit 1A) must be obtained before any assessments are performed. 3. The subject was capable of performing reproducible spirometry maneuvers as described by current American Thoracic Society Guidelines and had a post-ipratropium FEV 1 /FVC ratio <0.7 at Visit 1B. 4. Subjects with moderate to very severe stable COPD and a post-ipratropium FEV 1 less than 80% of predicted normal and a post-ipratropium FEV 1 >700 mL at Visit 1B. 5. Subjects with a current/past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years. 6. Subjects were willing and able to attend visits in accordance with the visit schedule. 7. Women of either childbearing potential or non-child bearing potential as follows:
Females of childbearing potential must have had documentation of a negative urine pregnancy test at Visit 1B and Visit 3 (before randomization). If a urine pregnancy test was positive, it must have been confirmed via a second urine pregnancy test. All female subjects of childbearing potential must have agreed to use a highly effective method of birth control during the trial and for at least 1 month after completion of drug dosing. o A highly effective method of birth control was defined as one that results in a low failure rate (i.e., <1% per year) when used consistently and correctly, such as condom þ diaphragm, condom þ spermicide, diaphragm þ spermicide, or intrauterine device with documented failure rate of <1% per year, or oral/injectable/ implanted hormonal contraceptives used in combination with an additional barrier method. Women were considered to be not of childbearing potential if they had a total hysterectomy and/or bilateral tubal ligation, (documentation for either must be provided before enrollment) or were at least 2 years postmenopausal. 8. Subjects (or caregivers) based on the investigator's assessment were able to properly prepare and administer medication based administered either by nebulizer or HandiHaler.
Exclusion criteria
1. Females who were pregnant, lactating, breastfeeding, or planning to become pregnant during the trial. 2. Subjects that had a significant respiratory disease or disorder other than COPD that, in the opinion of the investigator, would affect the interpretation of data from this trial, including, but not limited to, the following: Restrictive lung disorders Benign or malignant tumors of the lung Chronic pulmonary infections (e.g., tuberculosis) Occupational lung disease (e.g., silicosis, asbestosis) Inflammatory disorders of the lung, Alpha-1-antitrypsin deficiency, Abnormalities of the chest wall or musculature (e.g., scoliosis, myasthenia gravis, phrenic nerve palsy). 3. Subjects that had a history of cancer of any organ treated or untreated in the 5 years before Visit 1A (excludes localized basal cell or squamous cell carcinoma of the skin; localized prostate cancer in situ of Grade 1; localized cervical cancer in situ of Grade 0). 4. Subjects that had a concurrent disease or condition that in the opinion of the investigator would interfere with trial participation or confound the evaluation of safety, tolerability, or PK of the drug (revefenacin or tiotropium). 5. Subjects that had a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics or short-acting betaagonists. 6. Subjects that have any medical condition that would preclude the use of inhaled anticholinergics, including narrowangle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention. 7. Subjects that had a significantly increased risk of cardiovascular events, as indicated by a history at Visit 1A of myocardial infarction or unstable angina within the last 6 months, unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months, or New York Heart Association Class IV heart failure. 8. Subjects that had clinically significant and uncontrolled hypertension, hypercholesterolemia, or type II diabetes mellitus. 9. Subjects that had been hospitalized for COPD or pneumonia within 8 weeks before Visit 1B. 10. Subjects that had used systemic corticosteroids within 6 weeks of Visit 1B. 11. Subjects that had used antibiotics for respiratory tract infections within 6 weeks of Visit 1B. 12. Subjects that had undergone lung volume reduction surgery or lobectomy within 12 months before Visit 1B. 13. Subjects that had an abnormal and clinically significant 12-lead ECG finding at Visit 1B according to the following criteria: Atrial fibrillation with rapid ventricular rate >120 beats per minute Sustained or non-sustained ventricular tachycardia Second-degree heart block Mobitz type II Third-degree heart block (unless pacemaker or defibrillator had been inserted) QT interval corrected for heart rate using Fridericia's formula !500 msec. 14. Subjects that were unwilling or unable to stop the use of prohibited medications during the washout (if required), treatment period, or follow-up period. 15. Subjects that had participated in a previous revefenacin trial.
(continued on next page)
Inclusion and exclusion criteria
Subjects were eligible if they met the criteria in Table 2 .
Assessment of treatment-emergent AEs (TEAEs) and SAEs
A TEAE was defined as an AE that began on or after the date of the first dose of treatment (revefenacin or tiotropium) up to the date of the last dose of treatment plus 7 ± 2 days in the follow-up 16. Subjects that had used any other investigational medication within 30 days or 5 drug half-lives (whichever was longer) of screening. 17. Subjects that had a history of known or suspected alcohol or drug abuse within 2 years before screening, in the opinion of the investigator. 18. Subjects that were affiliated with the investigator site (e.g., investigator, trial coordinator, site employee). 19. Subjects that required long-term oxygen therapy (>15 hours a day) daily for chronic hypoxemia. 20. Subjects who participated in the initiation phase of a supervised pulmonary rehabilitation program (subjects in the maintenance phase were eligible).
COPD, chronic obstructive pulmonary disease; FEV 1 , forced expiratory volume in 1 second; FVC, forced vital capacity. period. Clinical severity was recorded and graded using mild, moderate, or severe. An SAE was defined as any adverse drug experience that occurred at any dose that resulted in any of the following outcomes in Table 3 . Clinical laboratory measurements and vital signs were performed non-fasting from Visit 1B to Visit 7 (and at Visit 8 if subject withdrew from subject early; Fig.) . Abnormal laboratory findings or other abnormal assessments (such as vital signs) that were associated with signs and/or symptoms or were considered clinically significant in the judgment of the Investigator, were recorded as AEs or SAEs if they met the definition of an AE (or SAE). Vital signs were summarized in terms of observed values and changes from baseline. Vital signs outliers are shown in Table 3 . 
Drug exposure
Using drug administration data from the electronic case report form, estimates of exposure to revefenacin and tiotropium were summarized in Table 4 .
Clinical laboratory measurements
Hematology and serum chemistry were assessed throughout the treatment period (Tables 5 and 6, respectively). A central laboratory (LabCorp Clinical Trials/COVANCE, Cranford, NJ) was used for all laboratory assessments.
Vital signs
Vital signs were assessed throughout the treatment period and were performed at approximately 60 minutes pre-dose and 10 minutes post-dose (Table 7) . Heart rate was discussed in a separate paper [2] .
